Michael Gelband’s Zevra Therapeutics ZVRA Stock Holding History

Michael Gelband’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-23,005	Closed	-$214K	–	2157
2026 Q1	$214K	Buy	+23,005	New	+$207K	﹤0.01%	1367
2025 Q4	–	Sell	-40,705	Closed	-$387K	–	2147
2025 Q3	$387K	Buy	+40,705	New	+$408K	﹤0.01%	1243
2025 Q2	–	Sell	-41,932	Closed	-$314K	–	2046
2025 Q1	$314K	Buy	+41,932	New	+$333K	﹤0.01%	1221
2024 Q4	–	Sell	-386,245	Closed	-$2.68M	–	2144
2024 Q3	$2.68M	Buy	+386,245	New	+$2.62M	0.02%	617

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Michael Gelband's ZVRA Position: Q2 2026 in Review

Michael Gelband sold out of Zevra Therapeutics (ZVRA) in Q2 2026, closing a stake of 23,005 shares — an estimated $214K sold.

Michael Gelband first reported a position in ZVRA in Q3 2024 and held it in 4 quarters. The position peaked at $2.68M in Q3 2024. 156 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Michael Gelband reported no remaining Zevra Therapeutics position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 23,005 Zevra Therapeutics shares in Q2 2026, an estimated $214K.
Michael Gelband first reported a position in Zevra Therapeutics in Q3 2024 and held it in 4 quarters.
Michael Gelband's Zevra Therapeutics position peaked at $2.68M in Q3 2024.
156 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.